您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > 4-iodo-SAHA
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
4-iodo-SAHA
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
4-iodo-SAHA图片
CAS NO:1219807-87-0
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
4-Iodo-SAHA (1k) 是一种具有口服活性的 I 类和 II 类组蛋白去乙酰化酶 (HDAC) 抑制剂,对 Skbr3、HT29、U937、JA16 和 HL60 细胞系的 EC50 分别为 1.1、0.95、0.12、0.24、0.85 和 1.3 μM , 分别。 4-Iodo-SAHA (1k) 可用于癌症的研究。
Cas No.1219807-87-0
别名ISAHA
化学名N1-hydroxy-N8-(4-iodophenyl) octanediamide
Canonical SMILESIC1=CC=C(NC(CCCCCCC(NO)=O)=O)C=C1
分子式C14H19IN2O3
分子量390.2
溶解度≥ 1.67mg/mL in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

4-iodo-SAHA is a hydrophobic derivative of SAHA, the class I and class II histone deacetylase (HDAC) inhibitor [1].

The reversible acetylation of lysine residues in histone plays an important role in transcriptional activation and repression. The regulation of these post-translational modifications is balanced by histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities. HDACs are also involved in reversible acetylation of non-histone proteins [1].

4-iodo-SAHA is a histone deacetylase (HDAC) inhibitor. In SKBR3-breast-derived cell line, 4-iodo-SAHA inhibited cell proliferation with EC50 value of 1.1 μM. In HT29 colon-derived cell line, leukemia-derived U937 tumor cell line, JA16, HL60 and K562 cell lines, 4-iodo-SAHA inhibited cell proliferation with EC50 values of 0.95, 0.12, 0.24, 0.85 and 1.3 μM, respectively. 4-iodo-SAHA is 10-fold more potent as an inhibitor of U937 leukemia cell proliferation compared to SAHA (0.12 μM versus 1.2 μM). In SKBR3 cells, 4-iodo-SAHA reduced acetylated H4 and p21 levels [1].

Reference:
[1].  Salmi-Smail C, Fabre A, Dequiedt F, et al. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. J Med Chem. 2010 Apr 22;53(8):3038-47.